Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favourable/Intermediate Risk: Multicentre Randomised Trial CROSS-J-RCC
Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2020.01.001
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2020
Authors
Publisher
Elsevier BV